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We conducted a phase I/II study in patients with advanced non-small-cell lung cancer (NSCLC) to increase the therapeutic index of
the cisplatin–irinotecan combination by institution of an anti-late-diarrhoeal program (ADP). A total of 77 chemotherapy-naive
patients with advanced NSCLC were enrolled. The cisplatin dose was fixed at 60mgm
 2 (Day 1). Irinotecan was escalated in
5mgm
 2 increments, starting from 60mgm
 2 (Days 1 and 8). ADP consisted of oral sodium bicarbonate, magnesium oxide, basic
water, and ursodeoxycholic acid, and was administered orally for 4 days with each dose of irinotecan. In the phase I portion,
irinotecan pharmacokinetics was also examined. After the recommended dose of irinotecan with ADP was determined, a phase II
study was conducted to evaluate the response. Maximum tolerated dose was reached at an irinotecan dose of 80mgm
 2 (Grade 4
diarrhoea and neutropenia). Pharmacokinetic studies show that the maximum concentration and the area under the curve of both
irinotecan and SN38 (active metabolite of irinotecan) tend to increase in the dose-dependent manner of irinotecan. The phase II
portion of the study included 48 patients, who were treated with 75mgm
 2 of irinotecan. Grade 3/4 toxicities included neutropenia
in 65%, leucopenia in 33%, and late diarrhoea in 6% of the patients. During this treatment, PS did not change in 65% of patients. At
the end of the chemotherapy, PS did not decline in 90% of patients. In the phase II portion, a response occurred in 63% (95%
confidential interval (CI), 47–76%) of patients. Median time to progression was 19 weeks (95% CI, 15–22 weeks), and median
survival was 52 weeks (95% CI, 39–64 weeks). This regimen of irinotecan and cisplatin with ADP resulted in promising efficacy with
acceptable toxicity for patients with advanced NSCLC. This regimen is a candidate for the experimental arm towards future phase III
studies.
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Lung cancer is a major health-care problem worldwide. Patients
with advanced non-small-cell lung cancer (NSCLC) have a poor
prognosis because this disease is incurable with currently available
treatments. Platinum-based two drug combinations improve
survival as well as the quality of life for patients with advanced
NSCLC (Non-small Cell Lung Cancer Collaborative Group, 1995).
However, an efficacy plateau has been reached with the currently
available two-drug combinations in the treatment of advanced
NSCLC (Schiller et al, 2002). Clinical trials are ongoing to
investigate novel combination chemotherapies to improve the
outcome for advanced NSCLC.
Irinotecan, a semisynthetic derivative of the plant alkaloid
camptothecin, exhibits antitumour activity by inhibiting topo-
isomerase I. Irinotecan has been approved for anticancer therapy
in the United States, Europe, and Japan (Garcia-Carbonero and
Supko, 2002). However, irinotecan is associated with toxicities,
including severe late diarrhoea and leucopenia (Fukuoka et al,
1992; Kobayashi et al, 1998). Some studies have documented
success with high-dose loperamide for treating irinotecan-asso-
ciated late diarrhoea (Bleiberg and Cvitkovic, 1996; Merrouche
et al, 1997). However, there is still no effective strategy for
preventing this dose-limiting adverse effect. Grade 3/4 late
diarrhoea occurs in 20–30% of patients treated with irinotecan
at the recommended doses (Fukuoka et al, 1992; Conti et al, 1996;
Saltz et al, 2000). Therefore, strategies to prevent late diarrhoea
should allow for more effective use of this drug.
Alkaline conditions within the intestinal lumen decrease
reabsorption of irinotecan and its metabolites (Kobayashi et al,
1999; Ikegami et al, 2002). The rationale was to prevent absorption
by oral alkalisation (OA), which should in turn reduce epithelial
damage and its impact on subsequent late diarrhoea. Controlling
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sdefecation (CD) should prevent constipation, thereby also
preventing epithelial disruption and allowing less time for
additional absorption. Based on these concepts, we conducted a
case–control study to evaluate the ability of OA and CD treatment
to prevent irinotecan-induced side effects (Takeda et al, 2001). A
multivariate analysis showed that OA and CD treatment reduced
the incidence of side effects such as late diarrhoea, emesis, and
leucopenia. Hence, we hypothesised that OA and CD could be
used as an anti-late-diarrhoeal programme (ADP) with irinotecan
therapy. We designed a novel regimen to increase the therapeutic
index of the cisplatin-irinotecan combination by decreasing the
toxicities of irinotecan and instituting ADP. The main objectives
of this study were to determine the maximum tolerated dose of
irinotecan and cisplatin with the use of ADP in the phase I portion
of the study and to evaluate the response rate of irinotecan and
cisplatin with ADP in chemotherapy-naive advanced NSCLC
patients in the phase II portion of the study.
PATIENTS AND METHODS
Patients
All patients had histologically or cytologically confirmed NSCLC.
Eligibility criteria included: (1) surgically unresectable, stage III
or IV disease; (2) no prior chemotherapy; (3) age 20–75 years; (4)
performance status (PS) p2 on the Eastern Cooperative Oncology
Group (ECOG) scale; (5) adequate bone marrow function
(leucocyte count 44000ml
 1; platelet count 4100000ml
 1;
haemoglobin concentration 49gdl
 1), hepatic function (bilirubin
o1.5mgml
 1; transaminases o2 upper limit of normal), and
renal function (creatinine o1.5mgdl
 1 and creatinine clearance
460mlmin
 1); (6) life expectancy of 8 weeks or longer; (7)
written informed consent; and (8) The presence of measurable
disease was necessary in patients with only stage IIIB or IV disease
who were enrolled in the phase II portion of the study.
Exclusion criteria were: (1) massive pleural effusion or cardiac
effusion (cardiac tamponade); (2) symptomatic brain metastases;
(3) prior surgery within 4 weeks; (4) uncontrolled comorbid
diseases such as angina pectoris, cardiac infarction within 3
months, cardiac failure, uncontrolled hypertension, uncontrolled
diabetes mellitus, active infectious diseases, ileus, interstitial
pneumonitis, or lung fibrosis; (5) concurrent malignancies; (6)
pregnancy or lactation; (7) inability to consume sodium and water
as required by ADP regimen. This protocol was approved by the
Institutional Review Board of the International Medical Center of
Japan.
Treatment
All patients were treated with combined chemotherapy consisting
of cisplatin and irinotecan delivered every 3 weeks. Cisplatin
(60mgm
 2) was administered intravenously on Day 1 after
adequate hydration. On Days 1 and 8, irinotecan was given in
500ml of normal saline as a 90min intravenously (i.v.) infusion.
All patients received the same antiemetic regimen, which consisted
of metoclopramide (10–20mgday
 1 for 4 days), corticosteroid
(4–5mgday
 1 betamethasone for 3 days), and 5-hydroxytrypta-
mine (5-HT3) receptor antagonist (1mgday
 1 granisetron for 2
days) given prophylactically by i.v. infusion before and after the
administration of chemotherapy. After that, oral administration of
5-HT3 antagonists (4mgday
 1 ondansetron) was continued for 4
days. The dose of irinotecan was withheld for leucopenia
(o3000ml
 1) and/or diarrhoea 4Grade 1. Granulocyte-colony-
stimulating factor (G-CSF) was administered when Grade 3
leucopenia (o2000ml
 1) and/or granulocytopenia (ol000ml
 1)
were observed. Before the next cycle was started, the leucocyte and
platelet counts had to be X3000 and 100000ml
 1, respectively. If
more than 6 weeks passed from the time of the last treatment
before these criteria were satisfied, the patient was removed from
the study.
The rationale for the ADP used in this study has been reported
in more detail elsewhere (Takeda et al, 2001). In brief, ADP was
started in the morning on Day 1 before irinotecan and cisplatin
administration and continued for 4 days. ADP consisted of sodium
bicarbonate, magnesium oxide, basic water, and ursodeoxycholic
acid (UDCA) administered orally. The former three agents have a
basic pH and directly mediate alkalisation from the duodenal
lumen. Ursodeoxycholic acid has been reported to stimulate bile
flow associated with a bicarbonate-rich choleresis and to increase
biliary pH (Strazzabosco et al, 1991). Magnesium oxide demon-
strates a laxative action, which was intended to shorten the
dwelling time of irinotecan and its metabolites within the intestine.
For OA, patients were given sodium bicarbonate 0.5g orally and
magnesium oxide 0.5g orally after every meal and before sleep, for
a total of four doses per day. Patients also took UDCA 100mg
orally after every meal, for a total of three doses per day, and basic
water (pH47.2) for a total of 1500–2000ml per day. Additional
magnesium oxide and basic water were also given to patients to
control defecation, with a goal of two bowel movements per day
(CD). If patients developed watery diarrhoea during ADP,
magnesium oxide administration was stopped. If diarrhoea
occurred on the day when irinotecan was administered, anti-
cholinergic drugs were used for treatment (Gandia et al, 1993).
Late diarrhoea, which occurred more than 6 days after each dose of
irinotecan administration, was treated with a high dose of
loperamide as described by Bleiberg et al (Bleiberg and Cvitkovic,
1996). Since irinotecan was administered on Days 1 and 8, we
defined late diarrhoea as occurring more than 6 days after
irinotecan administration and not explained by ADP-induced early
diarrhoea. ADP-induced early diarrhoea was defined by checking
the pH of the stool. If diarrhoea pH was alkaline during the period
of ADP, diarrhoea was thought to be from ADP (Takeda et al,
2001). If high-dose loperamide therapy did not stop late diarrhoea
altogether or if late diarrhoea of XGrade 3 appeared, the patient
was given fluid by intravenous hyperalimentation (IVH).
Study design
The doses of irinotecan were escalated in 5mg increments from
60mgm
 2, using three to six patient cohorts (Table 2). The first
dose level was 60mgm
 2 of irinotecan on Days 1 and 8 with
no ADP (60N). For the second level (60P) and beyond, patients
were treated with ADP. The maximum tolerated dose (MTD) was
defined as the dose at which dose-limiting toxicities (DLTs)
occurred in one-third, or more, of the patients. DLT was defined
as: (1) ECOG common toxicity criteria (CTC) Grade 4 leucopenia
or Grade 4 neutropenia lasting more than 5 days; (2) Grade 4
leucopenia or Grade 4 neutropenia with fever more than 381C; (3)
Grade 4 thrombocytopenia; (4) Grade 3 or 4 nonhaematological
toxicity (except for alopecia, nausea and vomiting, or constipation)
lasting more than 5 days; (5) Grade 2 diarrhoea lasting more than
7 days; or (6) Grade 3/4 diarrhoea. Once the MTD and the
recommended dose were defined, patients were accrued to the
phase II portion of the study. The primary end point of this phase
II study was response rate and secondary end points included time
to progression (TTP), survival and determination of toxicities.
Evaluation
Pretreatment evaluation included: PS, chest radiograph, bone
scintiscan, computed tomography of the head, chest, and abdo-
men, and fiberoptic bronchoscopy. Prior to each chemotherapy
cycle, patients were subjected to a complete blood cell count (CBC)
that included a differential count, serum chemistry for renal and
hepatic functions, electrolyte analysis, urinalysis, and PS. complete
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chest radiographs, and PS were assessed at least once a week after
the initial evaluation. PS was also checked at the end of each
chemotherapy cycle. During the cycle of chemotherapy, the pH
of diarrhoea was examined using a pH meter, HM-14P (TOA
Electronics Ltd, Tokyo, Japan) (Takeda et al, 2001) or pH test
sheet (Universal test paper or Brom-Thymol-Blue test paper;
Advantec, Toyo Roshi Kaisha Ltd, Tokyo, Japan). Tumour
response was classified in accordance with World Health
Organization criteria (World Health Organization, 1979). ECOG-
CTC was used to Grade toxicity. Duration for toxicities, measured
in this study, refers to the time required for recovery to toxicity
pGrade 1. The adherence of ADP was the average of the
compliance of water intake and drug intake. The compliance of
water intake was defined as: (total amount of water consumed)/
(amount of water intake prescribed). The compliance of drug
intake was calculated as the percentage of compliance with
medicines that were to be taken as scheduled for 3 days. Analysis
was conducted on an intent to treat for toxicity and efficacy profile.
Subtraction PS was to subtract the PS at certain time points of
chemotherapy from the PS at the start of chemotherapy. The
minus value of subtraction PS indicates declined PS. The plus
value indicates improved PS. Analyses on the follow-up data were
performed when more than two-thirds of the patients were dead or
12 months had passed since the enrollment of the last patients.
Time to progression was defined as the time from the date of
entry to the date of progressive disease, the last follow-up, or death
without progression. The duration of survival was determined as
the number of weeks from the date of entry to death or the last
follow-up.
Pharmacokinetics
Blood samples (5ml) were obtained from the arm opposite the one
used for chemotherapy infusion before the irinotecan infusion, at
the end of infusion, and 1, 2, 4, 8, 24, 48, 72h after completion of
the infusion. Serial plasma samples were acquired on the first cycle
from the patients. Sample collection started in each patient when
irinotecan was administered on Day 1. The blood was centrifuged
immediately, and the plasma obtained was stored at  801C until
analysis. Total plasma concentration of irinotecan, SN-38 (active
metabolite of irinotecan, 7-ethyl-10-hydroxycamptothecin), and
SN38 glucuronide (SN-38G) were measured using the high-
performance liquid chromatography method previously described
(Kurita and Kaneda, 1999). Maximum plasma concentrations
(Cmax, mgml
 1), elimination half-life (T1/2, hours), areas under
the plasma-concentration time curve (AUC0-N, mgh
 1ml
 1), and
mean resident time (MRT, hours) of each compound were
determined by noncompartment analysis using the computer
program, WinNonLin Professional version 4.1 (Pharsight Corpora-
tion, Mountain View, CA, USA).
Statistical analysis
We chose a target response probability for the regimen of 60% and
lowest response rate of interest to be 40%. According to the Simon
two-stage optimal design, a total of 46 patients were required to
test this hypothesis in the phase II portion. At least seven major
responses had to be observed in the first 16 assessable patients to
continue enrollment to the 2nd stage of the study (with type 1 and
2 errors of 0.05 and 0.20, respectively) (Simon, 1989). Patients not
assessable for response (because of treatment refusal or early
treatment discontinuation for any reasons other than progression)
were considered as nonresponders in calculation of the objective
response rate. We also calculated the 95% exact confidential
intervals (CIs) for response rate. Patients who received at least one
cycle of chemotherapy were considered evaluable for response.
Overall survival curves were estimated by the Kaplan–Meier
method (Kaplan and Meier, 1958). According to the report by
Schemper and Smith, median follow-up was estimated by reverse
Kaplan–Meier method (Schemper and Smith, 1996). All analyses
were performed using the Statistical Package for Social Sciences
(SPSS) for Windows 10.0J.
RESULTS
Patients
Between June 1997 and August 2002, 77 patients were enrolled at
the International Medical Center of Japan. In the phase I portion of
the study, all patients were evaluable for toxicities. In the phase II
portion, 48 patients were enrolled, and all were evaluable for
toxicity. In all, 71 patients had either stage IIIB or IV disease. Six
had stage IIIA disease. Patients’ characteristics are summarised in
Table 1.
In all, 21 patients were women, and the median age of all
patients was 64 years (range, 36–75 years). Of patients, 93% had a
PS of 0 or 1. Three patients had undergone prior surgical resection
(palliative surgery). One patient had received prior palliative
irradiation therapy to brain metastasis.
DLTs and MTD
In all, 29 patients received 61 cycles of chemotherapy in the phase I
portion of the study (mean 2, range 1–4) (Table 2). There were no
treatment-related deaths. Two of seven (29%) patients enrolled in
dose level 60N experienced Grade 4 neutropenia lasting 6 and 7
days, respectively. In that the objective of this portion of the study
was to determine the MTD for the combination with the use of
ADP, dose escalation continued. There were no DLTs in patients
treated in cohorts 60P and 65P. At 70P, only one of four patients
Table 1 Patients’ characteristics
Phase
Characteristics I II Total
Sex (n)
Male 21 35 56
Female 8 13 21
Age (years)
Median 66 62 64
Range 36–73 36–75 36–75
ECOG PS (n)
01 0 1 0 2 0
11 6 3 6 5 2
23 2 5
Histology (n)
Adenocarcinoma 25 35 60
Squamous cell carcinoma 3 9 12
Large cell carcinoma 1 4 5
Prior treatment (n)
No 22 47 69
Yes 7 1 8
Surgery 6 1 7
Extrathoracic RT 1 0 1
Stage (n)
IIIA 4 2 6
IIIB 4 12 16
IV 21 34 55
n, number of patients; RT, radiation therapy.
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days, though it did not meet the definition of DLTs). At 75P, one of
six patients (17%) experienced a DLT (Grade 3 serum glutamic
oxaloacetic and glutamic pyruvic transaminases for 8 days). Two
patients were enrolled in level 80P, and both of them experienced
DLTs; one patient had Grade 4 leucopenia with fever, Grade 4
diarrhoea and Grade 3 delusions, and the other had Grade 4
diarrhoea and Grade 4 neutropenia with fever. Two consecutive
patients also had severe toxicities that met DLTs. Even if an
additional four patients were enrolled into this level, more than
and equal to one-third of the patients experienced DLTs. The
safety committee recommended not continuing the entry of this
level. Therefore, the 80P was defined as the MTD and 75P was
decided as the recommended dose for phase II studies. The
adherence on ADP was more than 90% in patients treated in
cohorts 60P to 75P, and all of the patients in those levels exhibited
Grade 2 or less late diarrhoea. At the 80P dose level, severe nausea
impaired adherence with ADP. Irinotecan dose actually delivered
is listed in Table 2. Two patients (7%) could not be given
irinotecan on Day 8, and three patients (10%) had its administra-
tion delayed by a few days. The median recovery period from side
effects was 22 days (range, 17–30 days) in all patients enrolled
onto the phase I portion of the study. G-CSF administration was
required in 17% of the patients.
Pharmacokinetics
Pharmacokinetic studies were performed in 17 patients receiving
the phase I portion from 60P to 80P (Table 3). The Cmax and AUC
of both irinotecan and SN38 tend to increase in a dose-dependent
manner (Figure 1). The correlations between the administrated
dose of irinotecan and the Cmax of both irinotecan and SN38 are
Table 2 Adherence and dose limiting toxicities (DLTs)
Irinotecan
given on Day 8
Dose level
Dose of
irinotecan
(mgm
 2)
ADP
#1
Adherence
median
(range, %) Delay Off
Delivered dose/
planned dose of
irinotecan
(average, %)
Actual recovery
period median
(range, days) With G-CSF
Blood
transfusion
Patients
with DLT
Phase I (First cycle)
60N 60 NE
#2 0/7 0/7 100 22 (19–30) 2/7 0/7 2/7
60P 60 116 (82–140) 0/5 1/5
a 90 22 (18–28) 1/5 0/5 0/5
65P 65 117 (91–123) 1/5
b 0/5 100 22 (22–22) 0/5 0/5 0/5
70P 70 106 (104–107) 0/4 1/4
c 88 22 (22–22) 0/4 0/4 0/4
75P 75 93 (82–101) 2/6
d 0/6 100 21 (17–30) 1/6 0/6 1/6
80P 80 67 (58–76) 0/2 0/2 100 24 (23–24) 1/2 0/2 2/2
Phase II
(per patient)
75 87 (64–104) 19/48 6/48 94 26 (17–42) 13/48 3/48 NE
Phase II
(all cycles)
75 92 (64–121) 26/140 6/140 97 23 (17–42) 18/140 6/140 NE
ADP
#1, anti-late-diarrhoeal programme; NE
#2, not evaluated.
aHaematologic toxicity.
bNonhaematologic toxicity (diarrhoea).
cNonhaematologic toxicity (herpes zoster
infection).
dNonhaematologic toxicity (diarrhoea and liver dysfunction).
Table 3 Pharmcokinetic parameters of irinotecan, SN38, and SN38G in the phase I portion
Dose level 60P 65P 70P 75P 80P
No. Pts
*1 53342
Irinotecan
Cmax
*2 768.0789.62 816.77200.3 853.37313.4 11857258.5 1275735.36
T 1/2
*3 9.6972.26 13.874.36 21.271.72 13.871.82 11.573.22
AUC
*4 402371919 34027355.4 394771585 571971912 59877703.1
MRT
*5 5.1371.40 5.6772.12 9.4270.50 6.1871.31 6.5170.42
SN38
Cmax 12.976.82 13.376.66 17.3710.5 18.176.99 19.474.77
T 1/2 11.174.38 14.270.72 11.479.69 17.373.99 19.070.05
AUC 127.57114 102.7712.9 124.77101.9 165.8780.4 303.07122.4
MRT 10.875.48 15.172.05 10.9710.4 16.874.40 22.771.97
SN38G
Cmax 72.4744.4 109.3791.0 60.0718.8 59.5715.9 59.377.42
T 1/2 12.972.71 14.373.26 17.673.83 12.272.14 17.771.44
AUC 10077751.6 14557886.8 10867182.4 993.77561.6 12907151.3
MRT 13.673.20 14.474.01 21.673.60 14.073.17 22.170.95
pts, patients; Cmax, maximun concentration (ngml
 1); T1/2, elimination half-life (h); AUC, area under the curve (ngml
 1h
 1); MRT, mean residence time (h).
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tendencies were observed in T1/2 and MRT of irinotecan. There
is no consistent tendency in T1/2 and MRT of SN38 and in all
parameters of SN38G.
Toxicities in Phase II
In all, 48 patients and 140 cycles of chemotherapy (mean 3, range
1–5) were given in the phase II portion of the study. Table 2 shows
the adherence of the therapy, recovery period, and additional
supportive procedures by patient and cycle. When we evaluated
these factors by patient, the worst values during the treatment
were shown. The median adherence with ADP was 87% per patient
(Table 2). Reduction of the irinotecan dose was performed in only
two patients. The Day 8 dose of irinotecan could not be
administered in 13%, whereas in 19 patients (40%) it was delayed.
The median recovery period from all side effects was 26 days
(range, 17–42 days). The toxicity data by patient and cycle are
described in Tables 4 and 5. The maximum toxicities during the
treatment are shown in terms of the data by patient. Grade 2 or
greater leucopenia occurred in 37 patients (77%), with Grades 3
and 4 leucopenia occurring in 15 patients (31%) and 1 patient
(2%), respectively (Table 4). Neutropenia XGrade 2 was observed
in 42 patients (88%), with Grades 3 and 4 neutropenia observed in
24 (50%) and seven (15%) patients, respectively. Febrile neutro-
penia, defined as Grade 3 or 4 neutropenia concomitant with
XGrade 2 fever, was observed in 11 patients (23%). As a result,
13 patients (27%) required G-CSF administration. Grade 3 or 4
anaemia was observed in nine patients (19%), and three patients
(6%) required red blood cell transfusions. Grade 3 or greater
thrombocytopenia was observed in only one patient. No patient
required a platelet transfusion.
Gastrointestinal toxicity was the most prominent nonhaemato-
logical toxicity (Table 5). Nausea (4Grade 1) was the most
common gastrointestinal toxicity, occurring in 65% of patients.
According to the protocol, ADP was not discontinued if Grade 1
diarrhoea occurred. Since early diarrhoea included diarrhoea
possibly related to ADP, the frequency of 4Grade 1 was 38%. Only
one patient had Grade 3 early diarrhoea, and she recovered from it
when ADP was stopped. Furthermore, late diarrhoea 4Grade 1
was observed in 10 (21%) patients. Grade 3 diarrhoea was observed
in three patients (6%), and no Grade 4 diarrhoea was observed.
Other Grade 3 or 4 nonhaematological toxicities were as follows:
fatigue (two patients), infection except febrile neutropenia (one
patient), liver dysfunction (toxicities of bilirubin, four patients;
toxicities of transaminases, six patients), and hyponatraemia (one
patient). There was no severe pulmonary toxicity noted in this
study.
In general, PS represents a common (albeit global) parameter of
change (Cella et al, 1993). In the phase II portion, PS was serially
checked during all cycles of the chemotherapy in each patient
(Figure 2). The subtraction PS during chemotherapy by patient
was calculated to subtract the worst PS during total cycles of
chemotherapy from the PS at the start of chemotherapy. Two (4%)
had a  2 value of subtraction PS during chemotherapy and 15
(31%) patients had a  1 value. Although 35% of patients had
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Figure 1 (A) Correlation between irinotecan dose (mgm
 2) and maximum plasma concentration of irinotecan (R
2¼0.88, P¼0.018). (B) Correlation
between irinotecan dose (mgm
 2) and maximum plasma concentration of SN38 (R
2¼0.92, P¼0.01). (C) Correlation between irinotecan dose (mgm
 2)
and AUC0-infinite of irinotecan (R
2¼0.73, P¼0.067). (D) Correlation between irinotecan dose (mgm
 2) and AUC0-infinite of SN38 (R
2¼0.66, P¼0.095).
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sdeclined PS, 65% of patients had no change in PS during this
treatment. The subtraction PS at the end was to subtract the PS at
the end of this regimen from the PS at the start of chemotherapy.
Five (10%) patients had a  1 value of subtraction PS at the end.
In all, 11 (23%) patients had a þ1 value. At the end of the
chemotherapy, 23% of patients had improved PS and 67% of
patients had no change in PS.
Efficacy
A total of 27 patients were evaluable for response in the phase I
portion of the study and all 48 of the patients in the phase II
portion (Table 6). In the phase II portion of the study, the response
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Table 4 Haematologic toxicities
Number of patients (cycles) with toxicity
Leukopenia Neutropenia Anemia Thrombocytopenia
Dose
level
No. Pts
a
(cycles)
Mean nadir
(Range: ll
 1)
Grade
2
Grade
3
Grade
4
Mean nadir
(Range: ll
 1)
Grade
2
Grade
3
Grade
4
Mean nadir
(Range:
gdl
 1)
Grade
3–4
Mean nadir
(Range:
 10
4ll
 1)
Grade
3–4
Phase I
60N 7 (13) 2806 (1000–4160) 3 (5) 3 (3) 0 1276 (324–2288) 2 (5) 1 (2) 2 (2) 10.7 (8.0–12.7) 0 18.3 (11.3–25.1) 0
60P 5 (8) 2123 (1300–3560) 3 (4) 1 (3) 0 877 (312–1940) 1 (1) 2 (5) 1 (1) 9.8 (8.7–13.3) 0 14.8 (8.0–18.8) 0
65P 5 (14) 3055 (2100–4700) 4 (8) 0 0 1204 (483–1998) 2 (3) 2 (6) 1 (1) 10.7 (8.5–13.5) 0 15.9 (9.4–26.8) 0
70P 4 (9) 3167 (2000–4050) 1 (1) 0 0 1367 (860–1789) 1 (4) 3 (3) 0 11.4 (9.5–13.7) 0 23.4 (16.9–35.6) 0
75P 6 (15) 2825 (1800–4080) 4 (9) 1 (1) 0 1303 (378–2489) 3 (4) 2 (5) 1 (1) 9.8 (8.0–12.1) 0 20.6 (8.7–33.6) 0
80P 2 (2) 1235 (400–2070) 1 (1) 0 1 (1) 446 (200–691) 0 1 (1) 1 (1) 11.7 (10.8–12.5) 0 12.6 (9.4–15.8) 0
Phase II 48 (140) 2926 (510–7290) 21 (64) 15 (22) 1 (2) 1303 (112–3612) 11 (49) 24 (42) 7 (10) 9.8 (5.7–13.6) 9 (14) 19.2 (4.9–45.5) 1 (1)
aNumber of patients (cycles).
Table 5 Nonhaematologic toxicities
Phase I
Phase II
Dose level
60N 60P 65P 70P 75P 80P
Number of
patients (cycles) 7 (13) 5 (8) 5 (14) 4 (9) 6 (15) 2 (2) 48 (140)
Fatigue
Grade 2 0 1 (1) 1 (1) 0 0 0 12 (16)
Grade 3 0 0 0 0 0 2 (2) 2 (2)
Grade 4 0 0 0 0 0 0 0
Nausea
Grade 2 5 (8) 3 (3) 3 (6) 3 (5) 5 (10) 0 24 (40)
Grade 3 0 1 (1) 0 1 (1) 0 2 (2) 7 (10)
Grade 4 0 0 0 0 0 0 0
Infection
Grade 2 1 (1) 0 1 (2) 2 (2) 1 (1) 0 9 (14)
Grade 3 1 (1) 0 0 0 0 0 1 (1)
Grade 4 0 0 0 0 0 0 0
+NPG
a X3 1 (1) 0 0 0 1 (1) 2 (2) 11 (13)
Early diarrhoea
Grade 2 1 (1) 1 (2) 1 (1) 1 (1) 3 (4) 0 17 (23)
Grade 3 0 0 0 0 0 1 (1) 1 (1)
Grade 4 0 0 0 0 0 0 0
Late diarrhoea
Grade 2 2 (2) 2 (2) 2 (3) 1 (1) 2 (3) 0 7 (9)
Grade 3 0 0 0 0 0 0 3 (3)
Grade 4 0 0 0 0 0 2 (2) 0
Total bilirubin
Grade 2 1 (1) 0 1 (2) 1 (3) 1 (1) 2 (2) 7 (13)
Grade 3 0 0 0 1 (1) 0 0 4 (4)
Grade 4 0 0 0 0 0 0 0
Transaminases
Grade 2 0 0 0 0 0 0 3 (5)
Grade 3 0 0 0 0 1 (2) 0 3 (6)
Grade 4 0 0 0 0 0 0 0
Hyponatremia
Grade 2 2 (3) 0 0 0 2 (2) 0 11 (17)
Grade 3 1 (1) 0 0 1 (1) 0 1 (1) 1 (1)
Grade 4 0 0 0 0 0 0 0
aNeutropenia grade.
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Figure 2 Change of performance status (PS) in each patient. *;
Subtraction PS is to subtract the PS at particular time points during
chemotherapy from the PS at the start of the chemotherapy. Plus value of
subtraction PS means improved PS. Minus value of subtraction PS means
declined PS. Open bars represent subtraction PS during chemotherapy,
which is to subtract the worst PS during total cycles in each patient from
the PS at the start of chemotherapy. Solid bars represent subtraction PS at
the end of the chemotherapy, which is to subtract the PS at the end of the
treatment from the PS at the start of chemotherapy
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srate was 63% (95% confidential interval (CI), 47–76%) by intent to
treat analysis. Among these 75 evaluable patients, one patient had
a complete response, 39 patients had a partial response, 23 patients
had stable disease, and 12 patients had progressive disease. The
overall response rate was 53% (95% CI, 41–65%).
As of November 2003, median follow-up was 56 months (95%
CI, 17–95 months). All other patients, except one patient in the
phase I portion of this study, were followed up. Median TTP was 19
weeks (95% CI, 14–25 weeks). Survival rates (1 and 2 years) were
59% (95% CI, 46–71%) and 23% (95% CI, 13–35%), respectively.
Median survival was 56 weeks (95% CI, 42–70 weeks).
For the 48 patients in phase II (Figure 3), median TTP was 19
weeks (95% CI, 15–22 weeks, Figure 3a). One-year and two-year
survival rates for the patients in phase II were 50% (95% CI, 35–
65%) and 21% (95% CI, 10–35%), respectively. Median survival
was 52 weeks (95% CI, 39–64 weeks, Figure 3b).
DISCUSSION
Although the DLTs of single agent irinotecan include leucopenia
and neutropenia, the principal toxicity is late diarrhoea. Its
irinotecan-induced late diarrhoea appears unexpectedly and is
unpredictable. We conducted a phase I/II study of irinotecan and
cisplatin with the addition of ADP to decrease late diarrhoea. The
first dose level of 60N is almost the same as the standard regimen
used in Japan (Noda et al, 2002). The standard regimen of this
combination chemotherapy consists of 60mgm
 2 cisplatin on Day
1 and 60mgm
 2 irinotecan on Days 1, 8, and 15, every 4 weeks.
Grade 3 or 4 late diarrhoea occurred in 16% of their patients
treated with cisplatin plus irinotecan and in none of their patients
treated with cisplatin plus etoposide. We chose to study cisplatin
in combination with irinotecan for the following reasons: (1)
platinum-based chemotherapy is standard first-line treatment for
advanced NSCLC; (2) the combination of cisplatin and irinotecan
is associated with a high incidence of late diarrhoea. (3) Toxicity
limited the delivery of the planned dose of irinotecan dose to less
than 59% of cycles (Masuda et al, 1998). The ability to deliver the
planned doses of irinotecan should lead to improvement of
the efficacy of this combination regimen. In our study, 97% of the
planned dose irinotecan dose by cycle was actually administered
(Table 2). We hypothesised that incorporation of ADP would
improve the delivery of the planned dose of irinotecan dose by
decreasing side effects although we were aware of the possibility
that altered metabolic clearance of irinotecan could result in
reduced efficacy (Mathijssen et al, 2001). Even if this were the case,
ADP could increase the actual usage of irinotecan. When the
administration dose of irinotecan was increased by use of ADP,
the AUC and the Cmax of irinotecan also increased (Figure 1).
The results of our pharmacokinetic study show that the AUC and
the Cmax of both irinotecan and SN38 tend to increase in the
dose-dependent manner of irinotecan. Related to this phase I/II
study, we also conducted another pharmacokinetic study to
compare PK parameters with or without ADP. The analysis
is ongoing using the noncompartment model. This preliminary
data is showing that MRT of irinotecan and T1/2 of SN38 in
high adherence of ADP were shorter than those in its low
adherence. We supposed that the dose escalation of irinotecan
could be performed by increasing the elimination of these two
compounds.
Table 6 Objective response rates
CR PR
CR+PR PD
Group No. of evaluable patients No. No. No. % No. %
Phase I
60N 7 0 1 1 14.3 2 28.6
60P 5 0 1 1 20.0 2 40.0
65P 4 0 3 3 75.0 0 0
70P 3 0 0 0 0 1 33.3
75P 6 1 3 4 66.0 0 0
80P 2 0 1 1 50 0 0
Phase II 48 0 30 30 62.5 (47.3–76.0)
a 7 14.6 (6.1–27.8)
Total 75 1 39 40 53.3 (41.4–64.9) 12 16.0 (8.5–26.3)
CR, complete response; PR, partial response; PD, progressive disease defined by WHO response criteria.
a95% confidential interval.
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Figure 3 Time to progression and survival of 48 patients enrolled in phase II. (A) Time to progression of patients in phase II. (B) Survival of patients in
phase II.
Irinotecan and cisplatin with anti-diarrhoeal programme
Y Takeda et al
1347
British Journal of Cancer (2005) 93(12), 1341–1349 & 2005 Cancer Research UK
C
l
i
n
i
c
a
l
S
t
u
d
i
e
sThere is one report in a phase II study of irinotecan and
cisplatin without ADP, that grade 3 or 4 leucopenia, neutropenia,
and late diarrhoea occurred in 32 (46%), 53 (80%), and 13
(19%), respectively, of 69 patients (Masuda et al, 1998). In the
phase II portion of our study, grade 3 or 4 leucopenia, neutropenia,
and late diarrhoea occurred in 33, 65, and 6% of patients,
respectively (Tables 4 and 5). Even though their dose schedule
was slightly different from ours, all of their major toxic effects
are lower in our study than those in the above study. When we
examined toxicities profile by cycle, grade 3 or 4 leucopenia,
neutropenia, and late diarrhoea occurred in 17, 37, and 2%
of cycles, respectively (Tables 4 and 5). A common parameter
of change is PS and it was predicted that the physical and
functional factor would show the most significant sensitivity to
change in PS (Cella et al, 1993). In case of FACT-G, change in PS
was related to physical, functional, and emotional factors but
not to the social or relational situation with the doctor. In the
EORTC QLQ-C30, the same relationship was observed (Aaronson
et al, 1993). Hence, PS was serially checked during all cycles of
this treatment by patients. Although 35% of patients temporally
had declined PS probably due to the side effects, the PS did
not change in 65% of patients during this treatment (Figure 2). At
the end of the chemotherapy, PS had not declined in 90% of
patients. These changes of PS might be feasible for patients who
received the cisplatin-based doublet chemotherapy (Aaronson
et al, 1993).
The response rate in our study was 63% in the phase II portion.
Median TTP was 19 weeks and median survival 52 weeks. When
we reviewed the patients enrolled in this study, there were two
patients with stage IIIA disease in the phase II portion. However,
in order to maintain the statistical power of this study, these
two patients could not be removed from the efficacy profile. In
order to compare the efficacy profiles with the other study, we
also analysed the data of 46 patients with IIIB/IV. The response
rate, median TTP, and median survival in them were 61% (95% CI,
45–75%), 18 weeks (95% CI, 15–21 weeks), and 52 weeks (95% CI,
40–65 weeks), respectively. There was a probability that these
efficacy profiles might be better than those previously reported
with other platinum-based combination regimens in phase II
studies (Berthaud et al, 1992; Johnson et al, 1996; von Pawel
et al, 1996; Masuda et al, 1998; Zalcberg et al, 1998; Bretti et al,
2002).
After this combination chemotherapy, 33 (69%) of 48 patients
in our phase II were given second-line chemotherapies. Only 5
(10%) patients were treated by docetaxel (Shepherd et al, 2000).
When these 5 patients were excluded, the median survival of 43
patients was 54 weeks (95% CI, 38–71 weeks). These data suggest
that second-line chemotherapy by docetaxel might not influence
the survival of patients in our study.
In conclusion, irinotecan and cisplatin can be made more
tolerable with ADP. The irinotecan and cisplatin with ADP resulted
in promising efficacy with acceptable toxicity. In order to prove
the efficacy of this regimen, a randomised phase III trial is
necessary.
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